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The pneumococcus is a leading pathogen infecting children and adults. Safe, effective vaccines exist, and they work by inducing
antibodies to the polysaccharide capsule (unique for each serotype) that surrounds the cell; however, current vaccines are lim-
ited by the fact that only a few of the nearly 100 antigenically distinct serotypes are included in the formulations. Within the se-
rotypes, serogroup 6 pneumococci are a frequent cause of serious disease and common colonizers of the nasopharynx in chil-
dren. Serotype 6E was first reported in 2004 but was thought to be rare; however, we and others have detected serotype 6E among
recent pneumococcal collections. Therefore, we analyzed a diverse data set of1,000 serogroup 6 genomes, assessed the preva-
lence and distribution of serotype 6E, analyzed the genetic diversity among serogroup 6 pneumococci, and investigated whether
pneumococcal conjugate vaccine-induced serotype 6A and 6B antibodies mediate the killing of serotype 6E pneumococci. We
found that 43% of all genomes were of serotype 6E, and they were recovered worldwide from healthy children and patients of all
ages with pneumococcal disease. Four genetic lineages, three of which were multidrug resistant, described90% of the serotype
6E pneumococci. Serological assays demonstrated that vaccine-induced serotype 6B antibodies were able to elicit killing of sero-
type 6E pneumococci. We also revealed three major genetic clusters of serotype 6A capsular sequences, discovered a new hybrid
6C/6E serotype, and identified 44 examples of serotype switching. Therefore, while vaccines appear to offer protection against
serotype 6E, genetic variants may reduce vaccine efficacy in the longer term because of the emergence of serotypes that can evade
vaccine-induced immunity.
The pneumococcus (Streptococcus pneumoniae) is one of themost important pathogens worldwide. An estimated 1.3 mil-
lion children die every year from pneumonia, and the pneumo-
coccus is the leading cause (1, 2). It is also a leading cause of death
due to bacteremia and meningitis among young children and is a
major cause of disease among adults, particularly the elderly,
among whom there is also a high risk of death (3, 4). Pneumococ-
cal conjugate vaccines (PCVs) are administered to children in
many developed and resource-poor countries and have been an
enormous public health success, significantly reducing morbidity
andmortality in the countries that have implemented widespread
vaccination (5, 6).
Pneumococci are differentiated by an antigenic polysaccharide
capsule (“serotype”) that surrounds the cell and protects the
pneumococcus from being phagocytosed by the human immune
system. The polysaccharide capsule is an essential pneumococcal
virulence factor and forms the basis for PCV-mediated protection
against pneumococcal disease. The first PCV (PCV7) was licensed
in 2000 and included seven serotypes: 4, 6B, 9V, 14, 18C, 19F, and
23F (7). PCV7 was later superseded by PCV13, which added sero-
types 1, 3, 5, 6A, 7F, and 19A to the original PCV7 (8), and PCV10,
which contains the original PCV7 serotypes plus serotypes 1, 5,
and 7F (9).
However, nearly 100 different serotypes have been character-
ized and new ones continue to be discovered (10–13). Current
PCV formulations have limited serotype coverage, and their use
has been associated with a significantly altered serotype distribu-
tion. Disease due to vaccine serotype pneumococci decreases, but
an increase in the proportion of disease caused by nonvaccine
serotype pneumococci has been observed, although there is het-
erogeneity in this serotype replacement disease phenomenon that
is not well understood (14, 15). Furthermore, the prevalence of
commensal (carriage) pneumococci in the nasopharynx, its eco-
logical niche, generally remains the same after PCVbut reorders in
favor of nonvaccine types (16). Vaccine escape is also possible, and
new genetic variants can spread rapidly (17–19). Consequently,
protection from pneumococcal disease remains a challenge.
Apart from two known exceptions (serotypes 3 and 37), the
polysaccharide capsule is synthesized by theWzx/Wzy-dependent
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pathway and the associated genes are located in the capsular poly-
saccharide synthesis (cps) locus. The majority of the genes in the
cps locus are present in all cps loci, and there are three genes in
particular, wciP, wzy, and wzx, that have serotype-specific alleles
(20, 21). Horizontal genetic exchange of all or part of the cps locus
sequence, between related and unrelated pneumococcal lineages,
has been well documented (17, 18, 22–25).
Serogroup 6 is a particularly important serogroup, as it is one
of the most common serotypes found in the nasopharynxes of
unvaccinated young children and is amajor cause of serious pneu-
mococcal disease among all age groups (5, 26). Serotypes 6A and
6B have been recognized for many decades, but more recently,
serotypes 6C and 6D, which are genetically similar to serotypes 6A
and 6B, were discovered (27–29). From a vaccine perspective, it
was shown that the serotype 6B antibodies elicited by PCV7 were
partially protective against serotype 6A but not serotype 6C
(15, 30, 31). However, PCV13-induced antibodies were shown
to elicit killing of serotypes 6A, 6B, and 6C (31, 32) and PCV10-
induced antibodies mediated the killing of serotype 6B and
possibly serotype 6A (15, 33). Serotype 6D pneumococci have
been reported infrequently, although their prevalence in South
Korea was estimated to be 10%, and a PCV7-induced cross-
protective immune response to serotype 6D was demonstrated
(34, 35). Serotypes 6F, 6G, and 6H have been described very
recently, and whether PCVs provide any protection against
these serotypes is unknown (10, 13).
The first report of serotype 6E pneumococci was by Mavroidi
et al., whose study explored sequence diversity and evolution
among serogroup 6 pneumococci. Internal fragments of the three
serotype-specific genes were sequenced in a diverse collection of
102 isolates of serotype 6A and 6B pneumococci. While they
found little sequence divergence between serotype 6A andmost of
the serotype 6B isolates, they did identify a group of what they
called “class 2” serotype 6B sequences, whichwere5%divergent
from the majority of serotype 6B isolates (36). Two subsequent
studies of serogroup 6 diversity and evolution in other pneu-
mococcal collections confirmed the existence of “class 2” sero-
type 6B or what one report called “6B-III” or possible “serotype
6E” strains (29, 37). Very recently, investigators have reported
serotype 6E pneumococci in several Asian countries (38–40).
As part of an ongoing vaccine impact study characterizing Ice-
landic pneumococci pre- and postimplementation of PCV10,
we also discovered serotype 6E strains. Furthermore, we inter-
rogated the genome sequences of several serotype 6B Pneumo-
coccal Molecular Epidemiology Network (PMEN) reference
strains and found that they all possessed a serotype 6E cps locus
sequence. As far as we are aware, the biochemical structure of
serotype 6E polysaccharide is not known.
Therefore, we compiled and investigated a large and diverse
data set of1,000 serogroup 6 pneumococcal genomes with three
aims: (i) to determine the prevalence, distribution, and epidemi-
ology of serotype 6E (as defined by the cps locus sequence); (ii) to
examine the genetics of the serogroup 6 cps locus and the molec-
ular epidemiology of serogroup 6 lineages; and (iii) to assess
whether the serotype 6B polysaccharides in PCV7 and PCV13 in-
duce the production of protective antibodies to serotype 6E.
MATERIALS AND METHODS
Pneumococcal genome data set.A data set of 1,059 assembled serogroup
6 pneumococcal genome sequences was compiled by using previously
FIG 1 Flowchart outlining the compilation of the pneumococcal genome
data set and corresponding cps locus sequences that were analyzed in this
study.
van Tonder et al.
2272 jcm.asm.org July 2015 Volume 53 Number 7Journal of Clinical Microbiology
 o
n
 July 30, 2015 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
published genomedata sets (41–47), GenBank sequence data (http://www
.ncbi.nlm.nih.gov/GenBank/), and unpublished genome data from an
ongoing vaccine impact study in Iceland (Fig. 1; see Table S1 in the sup-
plementalmaterial). The vaccine impact study is collecting pneumococcal
isolates from healthy children and from patients of all ages with pneumo-
coccal disease and sequencing 3,100 isolates with the Illumina platform.
Pre- and postvaccine pneumococci from 2009 to 2015 will be analyzed
and compared, and a report on the complete data set will be published in
due course. The genomedata set included four serotype 6B pneumococcal
reference strains from the PMEN collection (48) whose genome se-
quences were available (Table 1). The genomes from GenBank were
downloaded directly, and all other genomes in the data set were down-
loaded as raw sequence reads from the European Nucleotide Archive
(ENA), assembledwithVelvet (49), and deposited in the rMLST database,
which is powered by BIGSdb (50, 51). Corresponding metadata were
manually acquired from the original publications and matched to the
genome data. Genome sequence quality was assessed, and poor-quality
sequences (e.g., those with gaps or non-full-length gene sequences in the
cps locus) were removed, leaving 974 genomes for analysis. All of the
genome assemblies analyzed in the present study, with the corresponding
metadata, are available from the pneumococcal PubMLST website (http:
//pubmlst.org/spneumoniae/).
Serotyping based on the cps locus sequence. The cps locus sequences
for each of the serogroup 6 references (serotypes 6A to 6G) were obtained
from public databases (Table 1). The serotypes associated with each of the
974 serogroup 6 genomes were differentiated on the basis of the sequence
of the cps locus genes with an in-house serotyping pipeline. Briefly, fol-
lowing an initial screening against the serotype reference sequences, sero-
group 6 genomes were serotyped by identifying the following amino acid
residues and/or alleles specific for each serotype: serotypes 6A and 6B,
wciP195; serotypes 6C and 6D, presence ofwciN andwzy117; serotype 6E,
wzy220 (for additional details, see Fig. S1 in the supplemental material or
contact us).
Analyses of cps locus sequences. Thirteen cps locus genes were iden-
tified among all seven serogroup 6 reference sequences with cd-hit (52) by
using a sequence identity threshold of80%: wzg, wzh, wzd, wze, wchA,
wciO, wciP, wzy, wzx, rmlA, rmlC, rmlB, and rmlD (see Fig. S2 in the
supplemental material for phylogenetic trees for all 13 genes). Note that
wciNwas also present among all of the cps loci, but the and versions of
wciNwere highly divergent, as noted previously (29, 53). The serotype 6A
reference sequence for each of the 13 geneswas thenBLASTed (54) against
the study genome data set to extract the sequences of the 13 genes from
each genome. Pairwise estimates of evolutionary distance (p-distance;
number of nucleotide sites that differ between two sequences divided by
the total number of nucleotides compared) were calculated for each of the
13 genes in the 974 genomes, stratified by serotype.
The extracted cps locus sequences were aligned gene by gene with
Muscle (55) before being concatenated together to obtain a 12,271-bp
cps locus alignment for each of the 974 genomes. The concatenated
sequences were then input into FastTree2 to construct a cps locus
phylogeny by using a nucleotide general time-reversible model (56).
The resulting phylogeny was annotated with iTOL (57). The p-dis-
tances between the serogroup 6 cps locus reference sequences were
calculated withMEGA5 (58). Input sequences were 13,416 bp in length
and spanned the cps locus from the start of wzg through the end of
rmlD, including intergenic regions but excluding wciN, HG262 (pres-
ent in the cps locus of serotypes 6A, 6F, and 6G only), and HG263
(present in serotypes 6B and 6E only).
Genome-wide assessment of sequence diversity. The Genome Com-
parator module in BIGSdb was used to compare all 974 serogroup 6 ge-
nomes to the annotated reference genome 670-6B (NC_014498.1), also
known as PMEN2 or Spain6B-2. The BLASTn parameters were set to
70% sequence identity and 100% sequence alignment length (50). The
data were exported to an Excel spreadsheet that depicted the results of
sequence comparisons of each annotated coding sequence (here referred
T
A
B
LE
1
R
eferen
ce
P
M
E
N
a
gen
om
es
an
d
cps
locu
s
sequ
en
ces
u
sed
in
th
is
stu
dy
R
eferen
ce
O
th
er
n
am
e
ST
A
ccession
n
o.
Y
r
O
th
er
in
form
ation
P
M
ID
a
P
M
E
N
2
Spain
6
B-2
ST
90
A
T
C
C
700670;E
N
A
1988
A
bscess
in
h
u
m
an
patien
t,M
adrid
8885390;11427569
P
M
E
N
8
S.A
frica
6
B-8
ST
185
A
T
C
C
700675;E
N
A
1990
H
u
m
an
blood
cu
ltu
re,Sou
th
A
frica
9442492;11427569
P
M
E
N
12
Fin
lan
d
6
B-12
ST
270
A
T
C
C
700903;E
N
A
1987
Isolated
in
Fin
lan
d
1398923;11427569
P
M
E
N
17
M
arylan
d
6
B-17
ST
384
A
T
C
C
B
A
A
342;E
N
A
1997
In
vasive
disease
isolate,U
n
ited
States
10608770
cps
locu
s
of
serotype:
6A
34351
R
odrigu
es
6A
/2
ST
7188
C
R
931638
1952
Isolated
in
U
n
ited
States
16532061
6B
2616/39
6B
/3
ST
7199
C
R
931639
1939
Isolated
in
D
en
m
ark
16532061
6C
C
H
P
A
388
E
F538714
1999–2002
N
asoph
aryn
gealisolate,U
n
ited
States
17576753
6D
M
N
Z
21
ST
282
H
M
171374
2008
Isolated
from
n
asoph
aryn
x
ofh
ealth
y
ch
ild,Sou
th
K
orea
20929956
6E
H
K
02-14
ST
90
M
u
ltiple
(accession
n
u
m
bers
for
each
sequ
en
ced
gen
e,see
referen
ce)
2008
Isolated
from
spu
tu
m
sam
ple,H
on
g
K
on
g
23824778
6F
M
N
Z
1135
P
S6657
K
C
832411
1992–2012
C
lin
icaladu
lt
sam
ple,G
erm
an
y
23897812
6G
M
N
Z
1136
P
S16864
K
C
832410
1992–2012
C
lin
icaladu
lt
sam
ple,G
erm
an
y
23897812
a
P
M
E
N
,P
n
eu
m
ococcalM
olecu
lar
E
pidem
iology
N
etw
ork;ST
,sequ
en
ce
type
as
determ
in
ed
by
m
u
ltilocu
s
sequ
en
ce
typin
g;P
M
ID
,P
u
bM
ed
iden
tifi
er.
Multidrug-Resistant Serotype 6E Pneumococci
July 2015 Volume 53 Number 7 jcm.asm.org 2273Journal of Clinical Microbiology
 o
n
 July 30, 2015 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
to as a “gene” for simplicity) in the reference 670-6B genome to each of the
974 query genomes. Data were output on a gene-by-gene basis across the
entire genome for every query genome. The 670-6B reference gene se-
quences were designated allele 1, and corresponding sequences in each
query genome were designated X (not present), 1 (identical to the refer-
ence), N (sequence present but nonidentical to the reference, assigned
allele numbers to indicate unique sequences), or T (sequence present but
truncated). The exported Genome Comparator gene-by-gene data anal-
ysis for the full 2.24-Mb genome was read into R (http://www.r-project
.org/) to create a pseudoheat map to compare gene presence or absence
and sequence diversity across all 974 genomes.
The Genome Comparator analysis also revealed that 432 gene se-
quences were found in all 974 genomes in the full coding length; thus, for
each of the genomes, these 432 genes were concatenated (292 kb in total)
and FastTree2 and ClonalFrameML (59) were used to assemble a phylo-
genetic tree that represented all 974 genomes. The resulting phylogeny
was annotated with iTOL. Multilocus sequence type (MLST) data were
available for each genome, and the sequence types (STs) were clustered
into clonal complexes (CCs) with Phyloviz (60) (see Table S1 in the sup-
plemental material). The 432-gene phylogenetic tree was annotated with
CC and serotype data for each genome.
Serological analyses of serotype 6E pneumococci. To evaluate func-
tional antibody responses to serotype 6E, sera collected after primary vac-
cination from PCV7 and PCV13 recipients (n  8) who participated in
previous vaccine studies (61, 62) were selected. Sera were analyzed by an
opsonophagocytosis assay (OPA; a titer of 1:8 is considered positive)
(63) utilizing five different isolates of serotype 6E pneumococci
(PMEN2 and PMEN8 plus three recent Icelandic isolates). To assess
the contribution of serotype-specific antibody in mediating the killing
of cross-reactive antigens, sera were retested by OPA after the sera were
adsorbed with purified serotype 6A, 6B (American Type Culture Col-
lection, Manassas, VA), or 6C capsular polysaccharide (Statens Serum
Institut, Copenhagen, Denmark) one at a time and reported as the titer
where 50% of bacteria were killed.
RESULTS
Epidemiology of serogroup 6 pneumococci. The study genome
data set represented a diverse set of 974 serogroup 6 pneumococci
TABLE 2 Epidemiological characteristics of individual serotypesa within 974 serogroup 6 pneumococcal genomes
Characteristic 6A 6B 6C 6D 6E Hybrid Total
No. (%) of isolates 318 (33) 108 (11) 115 (12) 4 (0.4) 421 (43) 8 974
Yr of isolation 1972–2013 2001–2013 2001–2014 2004 1981–2013 2008–2010 1972–2014
No. of isolates from:
Thailand 125 0 61 4 202 8 400
Iceland 118 100 14 0 130 0 362
United States 53 8 40 0 20 0 121
South Africa 19 0 0 0 10 0 29
Portugal 0 0 0 0 13 0 13
Germany 0 0 0 0 10 0 10
South Korea 0 0 0 0 8 0 8
Spain 0 0 0 0 7 0 7
China 0 0 0 0 6 0 6
Peru 0 0 0 0 6 0 6
Turkey 2 0 0 0 1 0 3
France 0 0 0 0 2 0 2
Finland 0 0 0 0 1 0 1
Oman 0 0 0 0 1 0 1
Papua New Guinea 1 0 0 0 0 0 1
Unknown 0 0 0 0 4 0 4
No. of isolates recovered from:
Carriage 247 80 107 4 229 8 675
Disease 67 28 8 0 164 0 267
Unknown 4 0 0 0 28 0 32
Patient age (yr)b 0.5–87 0.5–83 0.5–82 unknown 0.5–87 unknown 0.5–87
No. of isolates recovered:c
Before PCV 227 73 69 4 379 8 760
After PCV 89 35 46 35 205
Unknown 2 7 9
MIC (g/ml)d of:
Penicillin 0.03–16 0.03–0.06 0.03–1 Sd 0.03–4 0.06–1 0.03–16
Erythromycin 0.03–16 0.03–0.06 0.03–2 0.03–256 0.03–256
Tetracycline 0.5 to4 0.5–0.25 0.5–0.25 0.5–64 0.5–64
Chloramphenicol 2 2 2–4 2 to8 2 to8
a Serotypes were determined from the nucleotide sequence of the cps locus. No pneumococci of serotype 6F or 6G were identified in the study genome data set. The hybrid serotype
is genetically a combination of the serotype 6C and 6E cps locus sequences (see Results).
b Age data were missing for 625 genomes, but available data indicated that isolates of serotypes 6A, 6B, 6C, and 6E were recovered from both children and adults.
c Vaccine status refers to whether any pneumococcal conjugate vaccine (PCV) was being used in the country of origin at the time of pneumococcus isolation.
d Susceptibility data were missing for many genomes, but the ranges of available data are given here. S, susceptible. See Table S1 in the supplemental material for more details.
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recovered in 16 different countries across five continents between
1972 and 2014 (Table 2). Of the pneumococci recovered from
individuals spanning a wide range of ages, 69% (n  675) were
from colonized individuals and 27% (n  267) were from indi-
viduals with disease. A total of 78% (n  760) of the pneumo-
cocci were collected prior to any PCV introduction in the
country of origin. Antibiogram data demonstrated a range of
antimicrobial-susceptible and -resistant isolates among the se-
rotypes, although susceptibility data were missing for many of
the pneumococcal genomes. For the full list of genomes and
associated metadata, see Table S1 in the supplemental material.
A majority of the pneumococci in this study were originally
serotyped by the Quellung and/or latex agglutination methods.
See Fig. S3 in the supplemental material for a comparison of the
serotype distributions among all 974 genomes using the origi-
nal serotyping data versus sequence-based serotyping (sero-
type deduced on the basis of the cps locus sequence).
Sequence-based analysis of the data set revealed that 421 of the
974 pneumococci were serotype 6E. They were recovered from
individuals between the ages of 6 months and 87 years residing in
15 different countries in Europe, North America, South America,
Africa, and Asia (Table 2). The serotype 6E pneumococci were
isolated from 1981 onward, and 90%were isolated prior to the use
of any PCVs. Serotype 6E isolates were recovered from both
healthy young children and individuals of all ages with pneumo-
coccal disease. The diseases caused by serotype 6E pneumococci
spanned the range of typical pneumococcal diseases, i.e., otitis
media, sinusitis, empyema, pneumonia, bacteremia, and menin-
gitis (see Table S1 in the supplemental material).
One-third (n  318) of the genomes were serotype 6A pneu-
mococci recovered between 1972 and 2013 from patients of all
ages residing in six different countries. The majority of the sero-
type 6A pneumococci were recovered from healthy children, al-
though 67 isolates from patients with invasive and noninvasive
diseases were also included (Table 2; see Table S1 in the supple-
mental material). Pneumococci with a serotype 6C cps locus se-
quencemade up 12% (n 115) of the data set andwere recovered
predominantly from healthy children in Thailand, Iceland, and
the United States since 2001.
Eleven percent (n  108) of the pneumococci possessed a
serotype 6B cps sequence. Serotype 6B pneumococci were iso-
lated between 2001 and 2013 from both carriage and disease
(otitis media, pneumonia, and bacteremia), from patients of a
wide range of ages. Four serotype 6D pneumococci from Thai-
land were identified among the genomes, but no serotype 6F or
6G pneumococci were identified. Eight carriage pneumococci
from Thailand with a hybrid serotype 6C/6E cps locus were also
identified, and these are discussed in more detail below.
Serotype-specific prevalence estimates. The study genome
data set was diverse and compiled from several different genome
collections; thus, estimates of serotype-specific prevalence based
on the entire data setmay not be representative of the global pneu-
mococcal population. However, the carriage data sets from the
Maela refugee camp in Thailand and from Massachusetts could
reliably be used to assess the prevalence of serotypes within spe-
cific geographic locations during a specified time period.
TheMaela genomedata setwasmade upof 3,085 pneumococci
collected from infants and mothers living in a rural refugee camp
FIG 2 Organization of the cps locus for each of the seven serogroup 6 reference sequences (Table 1 contains the accession numbers). Red arrows are the 13 genes
common to all serogroup 6 cps loci at80% sequence similarity,wciN is blue, and the or allele is indicated, transposons and other pseudogenes are gray, and
a hypothetical gene (hyp) is orange. The  and  versions of wciP are also indicated.
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in Thailand from2007 to 2010 (41, 64). PCVs hadnot been used in
this setting prior to or during the study period. Three hundred
ninety-eight serogroup 6 pneumococcal genomes were identified,
of which 50% (n  200) were serotype 6E, 31% (n  125) were
serotype 6A, 15% (n  61) were serotype 6C, 1% (n  4) were
serotype 6D, and 2% (n 8) were the hybrid 6C/6E serotype (see
Table S1 in the supplemental material). No pneumococci with a
serotype 6B cps locus sequence were identified.
In contrast, 616 pneumococcal genomes were collected from
healthy young children in Boston, MA, during three time periods
(2001, 2004, and 2007) after the implementation of PCV7 (42).
Ninety-seven serogroup 6 pneumococci were identified, of which
47% (n 46) were serotype 6A, 35% (n 34) were serotype 6C,
9% (n  9) were serotype 6E, and 8% (n  8) were serotype 6B
(see Table S1 in the supplemental material).
Serotypes among PMEN clones. Genome sequences of four
PMEN reference strains were included in this study, PMEN2
(Spain6B-2), PMEN8 (S. Africa6B-8), PMEN12 (Finland6B-12),
and PMEN17 (Maryland6B-17), as shown in Table 1 (48; http:
//pubmlst.org/spneumoniae/). All four were previously identified
as serotype 6B on the basis of theQuellung reaction, but all possess
a serotype 6E cps locus sequence. Note that the cps locus sequence
of Poland6B-20 was not yet available and the genome sequence of
Greece6B-22 was incomplete for some of the cps locus genes and
thus could not be analyzed in this study. Moreover, one data set
included in this study was compiled specifically to study the
PMEN2 lineage (43), which is a multidrug-resistant lineage of
pneumococci detected in many countries around the world but
was originally identified in Iceland and Spain in the 1980s
(http://pubmlst.org/spneumoniae/). One hundred eighty-nine
pneumococcal genomes were sequenced in the original PMEN2
study. One hundred seventy-two of these had complete cps locus
sequences and were thus included in the present study, and all
possessed a serotype 6E cps locus sequence.
Genetics and phylogeny of the cps locus. Thirteen cps locus
genes were common to all 974 serogroup 6 pneumococci at a
similarity threshold of80% (Fig. 2), and synteny was preserved
among all of the common genes. Pairwise distances (p-distances)
of nucleotide variation between the cps loci of the seven reference
strains were calculated, and notably, serotype 6E was 6.7% diver-
gent (p-distance range, 0.065 to 0.068) from all of the other sero-
types, whereas the divergences between all of the other serotypes
were 0.4 to 1.7% (Table 3). The p-distances were also calculated
individually for each of the 13 common genes by using the entire
974-genome data set stratified by serotype, and the median p-dis-
tance value was used to provide a simple summary statistic of
gene-specific sequence diversity within each serotype (Table 3).
Most notably, the serotype 6B, 6D, and 6E cps gene sequenceswere
highly conserved within each serotype (median p-distance per
gene 0), whereas nearly all of the cps locus genes of the serotype
6A and 6C isolates varied to some extent, withwzg, rmlA, and rmlB
being the most diverse (in addition to wciN), as noted in a previ-
ous study (37).
A phylogenetic tree was constructed with concatenated se-
quences of the 13 common cps locus genes for each of the 974 ge-
nomes, and major serotype clusters were clearly delineated (Fig. 3).
There were three major serotype 6A clusters and one cluster each
for serotypes 6B, 6C, and 6D. No serotype 6F or 6G pneumococci
TABLE 3 Estimates of pairwise evolutionary distances between serogroup 6 cps locus sequences and among individual genes within the cps locus of
each serotype
cps locusa or geneb
Evolutionary distance from indicated serotypec
6A 6B 6C 6D 6E 6F 6G
6A — 0.008 0.016 0.011 0.068 0.009 0.010
6B 0.008 — 0.011 0.016 0.065 0.008 0.004
6C 0.016 0.011 — 0.012 0.066 0.010 0.013
6D 0.011 0.016 0.012 — 0.068 0.012 0.017
6E 0.068 0.065 0.066 0.068 — 0.067 0.067
6F 0.009 0.008 0.010 0.012 0.067 — 0.009
6G 0.010 0.004 0.013 0.017 0.067 0.009 —
wzg 0.013 0 0 0 0 — —
wzh 0.008 0 0 0 0 — —
wzd 0.001 0 0.001 0 0 — —
wze 0.004 0 0.009 0 0 — —
wchA 0.004 0 0.007 0 0.001 — —
wciN 0.001 0 — — 0 — —
wciN — — 0.002 0 — — —
wciO 0 0 0.006 0 0 — —
wciP 0 0 0.002 0 0 — —
wzy 0.001 0 0.004 0 0 — —
wzx 0.001 0 0.001 0 0 — —
rmlA 0.046 0 0.062 0 0 — —
rmlC 0.005 0 0.002 0 0 — —
rmlB 0.016 0 0.014 0 0 — —
rmlD 0.005 0 0.006 0 0 — —
a Pairwise comparisons were made between the serogroup 6 references by using 13,416-bp cps locus sequences, which spanned the cps locus from the start of wzg through the end of
rmlD but excluded wciN, HG262, and HG263 from the analysis (see Materials and Methods and Fig. 2).
b Median pairwise distances for each cps locus gene were estimated by using the entire 974-pneumococcal-genome data set but stratified by serotype. No serotype 6F or 6G
pneumococci were identified among the study genomes.
c —, data not available.
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were identified, but the serotype 6F and 6G reference sequences
were within serotype 6A clusters. This was consistent with the
initial report describing these new serotypes as being nearly iden-
tical to the serotype 6A cps sequence (10). The serotype 6E pneu-
mococci clustered in one group withminor within-cluster genetic
variation, apart from a few pneumococci from South Africa in
1984 and 1985 andMassachusetts in 2004 (long purple branches)
that had switched serotypes and are discussed below, and three
Thai pneumococci at the tips of very short branches that possess
predominantly the serotype 6E cps locus sequence but also have
sequence regions that match the serotype 6C or 6D sequence.
There was also a small cluster (colored gray) of eight pneu-
mococci collected in Thailand from 2008 to 2010. This small
cluster represented a hybrid serotype 6C/6E cps locus, with
sequence differences as shown in Fig. 4. The hybrid failed to be
classified properly as either serotype 6C or serotype 6E in the
serotyping pipeline because it possessedwciN like serotype 6E
but the wzy-encoded amino acid sequence that differentiates
serotype 6C (Fig. 4A). The reason for this serotyping failure
was clearly apparent when the sequences for each of the cps
locus genes was examined (Fig. 4B). The hybrid predominantly
matches the serotype 6E sequence but contains a region of
mainly serotype 6C-like sequence from wciP through roughly
the first half of wzx.
Molecular epidemiology of serogroup 6 pneumococci. A
phylogenetic tree was constructed on the basis of 432 concate-
nated gene sequences (292 kb) present in full coding length in
all 974 pneumococci (Fig. 5). The tree was annotated by using
CC and serotype data, which clearly defined the major CCs
(those with 12 members) within the data set. The serotype
data, represented by the outer colored ring, demonstrated
which serotypes were associated with each CC and where sero-
type switching had occurred within CCs.
Serotype 6E pneumococci were associated with 20 CCs (43
sequence types [STs]) in the study data set, although 89% of the
serotype 6E pneumococci were members of one of four lineages,
CC90 (n 203); CC315 (n 117); CC4405 (n 55); and CC273
(n 20), as shown in Fig. 5 (also see Table S1 in the supplemental
material). CC90, CC315, and CC273 are multidrug-resistant lin-
eages associated with PMEN2, PMEN20 (Poland6B-20), and
PMEN22 (Greece6B-22), respectively (see Table S1 in the supple-
mental material; http://pubmlst.org/spneumoniae/). All eight hy-
FIG 3 Phylogenetic tree depicting the relationships between the concatenated sequences of 13 common cps locus genes (12.3 kb) among 974 serogroup 6
pneumococcal genomes. Serotypes are colored according to the legend in the top left corner.
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brid serotype 6C/6E genomes were ST315. Notably, pneumococci
of these four serotype 6E lineages have been detected in at least 32
different countries on six continents, as detailed in the PubMLST
database. However, the majority of the isolates of these four lin-
eages in PubMLST were submitted as serotype 6B (including
PMEN20 and PMEN22); these should be considered putative se-
rotype 6E rather than serotype 6B, and thus, the PubMLST data-
base expands the wide distribution of serotype 6E pneumococci.
Serotype 6A pneumococci were members of 24 different CCs
(45 STs) in the study data set, of which 11CCs captured 90%of the
serotype 6A population (see Table S1 in the supplemental mate-
rial). Serotype 6C pneumococci were associated with 12 CCs, 5 of
which defined 83% of the serotype 6C genomes. All but three
strains of serotype 6B pneumococci were members of either
CC176 (n  66) or CC138 (n  39), and all four serotype 6D
genomes were ST4407.
Serotype switching among serogroup 6 pneumococci. There
was clear evidence of serotype switching (horizontal genetic
exchange of all or part of the cps locus sequence, conferring a
change in serotype) within 11 CCs, since pneumococci within
the CC were not exclusively defined by a single serotype (Fig. 5
and 6). Notably, CC315 was represented by three serotypes:
serotypes 6E and 6C and the serotype 6C/6E hybrid. CC90 was
defined predominantly by serotype 6E pneumococci, except for
nine genomes from the Maela refugee camp that were ST5127
(a double-locus variant of ST90) and had a serotype 6A cps
locus. CC1094 was a major South African lineage of serotype
6A, although three genomes isolated in the mid-1980s were
serotype 6E.
The cps locus sequences of all 44 genomes associated with
putative serotype switches were manually inspected and con-
firmed. All serotype switches were clearly evident from the se-
quence, either by an exchange of the entire cps locus or by
mosaic patterns of DNA sequence fragments indicative of re-
combination events within the cps locus (see Fig. S4 in the
supplemental material) (17, 18, 22–25). No other hybrid cps
loci were identified apart from the serotype 6C/6E hybrid de-
scribed above.
Genome-wide diversity among serotypes. Finally, all 974 ge-
nomes were compared to the PMEN2 genome reference with
the Genome Comparator module of BIGSdb to investigate the
presence or absence and diversity of 2,352 genes across each
genome. These data were depicted as a pseudoheat map, or-
dered by serotype and CC (Fig. 7). A number of observations
were immediately apparent. As expected, the genomes of
CC906E (CCserotype) pneumococci were very similar to the
PMEN2 reference (ST906E) genome used for comparison (largest
white horizontal band). However, they were not identical—the
bacteriophage sequences in the PMEN2 reference were either not
present or of a different sequence in the CC906E study pneumo-
cocci, and there was a region of variable genes (blue) in the latter
half of the genome in addition to several smaller variable re-
gions in some genomes within CC906E. The serotype switch
CC906A pneumococci were highly similar across the genome to
the CC906E pneumococci, although CC906A genomes also did
not have the PMEN2-like bacteriophages and smaller variable
regions were identified. The STs within CC2736E, CC44056E,
and CC4906A had some MLST alleles (5, 1-4, and 1, respec-
tively) in common with the STs in CC90, but all possessed
genes across the genome that matched CC906E identically
(genes colored white). In contrast, across the genome, the
CC3156E genes were mainly of different alleles (i.e., mainly
genes colored blue). Future studies will use these genome-wide
data to investigate whether specific genotypic differences among
serogroup 6 lineages relate to phenotypic differences between lin-
eages and/or serotypes.
FIG 4 Illustration of the genetic organization, nucleotide similarity, and variable amino acids of the hybrid serotype 6C/6E cps locus sequence. (A) Comparison
of the hybrid cps locus sequence to the reference serotype 6C and 6E sequences. The results of pairwise BLAST nucleotide sequence comparisons are shown;
darker gray indicates greater conservation between the pair of sequences. (B) Variable amino acid residues identified among the serotype 6C and 6E and hybrid
sequences. The position of each variable residue in an alignment of conceptually translated amino acid sequences is indicated by the number above the residue.
The residues associated with serotype 6E and 6C are purple and orange, respectively, and those not found in either serotype 6E or serotype 6C are gray. Note that
the wciN allele is simply indicated as  or  and that rmlB and rmlD were identical across all three sequences.
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Vaccine-induced inhibition of serotype 6E. Finally, a key
question was whether or not PCVs would provide immunological
protection against serotype 6E pneumococci. Stored sera from
infants in the United Kingdom who had previously been vacci-
nated with either PCV7 or PCV13 were available and used to test
for killing of serotype 6E pneumococci. Five strains were tested,
and the results are shown in Table 4. Antibodies induced by both
PCV7 and PCV13 mediated the killing of the five strains tested.
Removal of antibodies specific for serotype 6B polysaccharide
abolished the killing completely in most of the sera tested. Re-
moval of serotype 6A antibodies varied by serum analyzed but in
general was similar, irrespective of the type of vaccine used (6B
alone in PCV7 or both 6B and 6A in PCV13), with only partial
inhibition of killing demonstrated, findings consistent with those
of a previous study of serotype 6A inhibition of serotype 6B killing
(31). Anti-serotype 6C antibody removal also varied depending
on the serum used but in general had little effect on killing.
DISCUSSION
This is the first in-depth large-scale interrogation of the genomic
epidemiology of serogroup 6 strains, and it illustrates that sero-
type 6E pneumococci have been circulating for at least 33 years,
preceding PCV introduction by nearly 2 decades. Our study re-
vealed that 43% of the genome collection (previously thought to
contain predominantly serotypes 6A, 6B, and 6C) in fact repre-
sented serotype 6E pneumococci of severalmajor genetic lineages,
three of which were multidrug-resistant PMEN lineages. They
were distributed across 15 countries and five continents, and the
FIG 5 Phylogenetic tree describing genome-wide relationships among serogroup 6 pneumococci. The tree was constructed with the concatenated
sequences of 432 full-length coding loci found in all 974 genomes and annotated with CC designations and serotypes. CCs with12 isolates are colored
as shown in the key at the upper left. The outer ring indicates the serotype by color as follows: 6A, blue; 6B, red; 6C, orange; 6D, light green; 6E, purple;
6F, light blue; 6G, pink.
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pneumococcal PubMLST database provides evidence of an even
wider geographical distribution. Serotype 6Epneumococci caused
a range of diseases among all age groups but were also frequently
recovered from healthy young children.We identified several ma-
jor genetic clusters of serotype 6A cps locus sequences, discovered
a new hybrid 6C/6E serotype, and revealed many examples of
serotype switching involving serotypes 6A, 6B, 6C, 6D, and 6E.
Importantly, serological assays demonstrated that vaccine-in-
duced serotype 6B antibodies were able to mediate the killing of
serotype 6E pneumococci.
For several decades, the existence of serotype 6E pneumococci
was obscured because they cross-react to the serotype 6B antisera
used in the Quellung reaction, and it was only by inspection of the
cps locus sequences that the existence of serotype 6E was realized.
Initially, serotype 6E was recognized by several research groups
analyzing key regions of gene sequenceswithin small collections of
isolates, and now the high prevalence and worldwide distribution
of serotype 6E has been revealed unequivocally here by the inter-
rogation of a global and historical collection of genome sequences.
Basically, the majority of what for many years were thought to be
serotype 6B isolates were in fact serotype 6E pneumococci. “True”
serotype 6B pneumococci were also identified in our study, but
they were mainly of two genetic lineages, CC138 and CC176,
both of which have also been detected in many countries around
the world (http://pubmlst.org/spneumoniae/).
Our study revealed the sequence diversity among serogroup 6
cps loci, and of particular note was the finding of three major
serotype 6A cps locus sequence clusters. Do the sequence-based
changes in the serotype 6A cps locus result in changes to the poly-
saccharide, and if so, do PCV-induced serotype 6A antibodies
differentially protect against alternative versions of serotype 6A
polysaccharide? This warrants further investigation. Moreover, in
this study, we discovered the serotype 6C/6E hybrid, which is suf-
ficiently divergent to presumptively consider it yet another sero-
type, as well as evidence ofmany distinct serotype switches among
the genetic lineages. Yet it is important to recognize that serotype
switching and the creation of cps locus genetic variants appear to
be normal biological processes among pneumococci and are not a
direct consequence of vaccine use (25). However, vaccine-in-
duced immune pressure does alter the pneumococcal population
structure, which can select for the emergence of new genetic vari-
ants. The earliest reported evidence of vaccine escape pneumo-
cocci was the result of such a scenario (17–19). PCVs perturb the
pneumococcal population with unpredictable consequences for
those serotypes not targeted by the vaccines; therefore, the impor-
tance of genomics and molecular epidemiology in any pneumo-
coccal surveillance program cannot be underestimated.
A detailed comparison of serogroup 6 polysaccharide bio-
chemistry should be investigated as a matter of priority, to under-
stand the biochemical structure of the polysaccharides in the con-
text of the observed serotype-specific epidemiology and killing
mediated by serotype 6B antibodies. It may be that the structures
of the serotype 6B and 6E polysaccharides are similar enough to
explain the inhibition of serotype 6E pneumococci by PCV-in-
FIG 6 CCs identified among the 974 pneumococcal genomes that were not of a single serotype.
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duced serotype 6B antibodies, even though at the sequence level
the cps loci are very different. However, Oliver et al. recently re-
ported a detailed investigation of new serotypes 6F and 6G and
experimentally showed that single changes in the amino acid se-
quence encoded by wciN resulted in changes in the repeating
units of the capsular polysaccharides, with concomitant changes
in the serological profiles. wciN and wciN are highly divergent
versions of wciN; serotypes 6A, 6B, 6E, 6F, and 6G possess wciN
(encoding a galactosyltransferase), while serotypes 6C and 6D
have the wciN allele (encoding a glucosyltransferase). The au-
thors concluded that small changes in the sequence not only re-
sulted in new capsular types, but they also posited that these
changes could confer immunological changes in the human host
response (10).
The majority of these serotype 6E study isolates were collected
before PCV implementation, and our study showed that PCV7-
and PCV13-induced antibodies to serotype 6B were protective.
Therefore, the overall prevalence of serotype 6E should be signif-
icantly reduced after PCV implementation, and PCV vaccine im-
pact studies in many countries have demonstrated a significant
reduction in the prevalence of serotype 6B and near elimination of
serotype 6B carriage (5, 6). This suggests the possibility that (i)
PCV7 and PCV13, which contain serotype 6B polysaccharides,
inhibit serotype 6B and sufficiently cross-protect against sero-
type 6E at the population level or (ii) the “serotype 6B” poly-
saccharides in the vaccines are actually serotype 6E polysaccha-
rides. We have been unable to identify which strain(s) was
specifically used to produce the serotype 6B polysaccharides
used in the PCVs, in order to confirm the serotype on the basis
of the cps locus sequence.
Whether or not current PCVs are, in fact, serotype 6E vaccines
remains an open and important question. The overwhelming suc-
cess of PCVs in reducing serotype 6B (6E) disease suggests that
perhaps the question is purely an academic one; however, it would
be relevant in cases of vaccine failure where there may be discor-
dance between the vaccine serotype and the serotypes of pneumo-
cocci associated with vaccine failure. One clue to a mismatch
might be if pneumococci responsible for serotype 6B vaccine fail-
ures were of the ST138 or ST176 lineage, as these appear to be the
predominant (true) serotype 6B lineages that circulate worldwide.
Country-specific estimates of the prevalence of serotype 6E before
and after PCV implementation will be essential to assessing
FIG 7 Visual representation of the Genome Comparator output for all 974 genomes as a pseudoheat map. Each genome is depicted horizontally and in
the gene order defined by the reference PMEN2 genome sequence, which has 2,352 coding sequences (genes). Colors indicate the gene-by-gene presence
or absence and sequence similarity of each query genome compared to the PMEN2 reference as follows: gray, the gene is not present in the query genome;
white, the gene is present in the query genome and has a sequence identical to that of the reference genome; blue, the gene is present in the query sequence,
but the sequence is not identical to that of the reference. Several regions of the PMEN2 reference genome are highlighted as follows: P1, phage remnant;
P2, 11865-like phage; P3, 2167-like phage; cps, capsular locus; A1, ATP-synthase operon; ICESp6BST90, ICE element; Variable, variable region of the gene
sequences in CC90-6E.
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TABLE 4 Results of serological assays using pediatric sera collected after primary PCV7 and PCV13 immunization to inhibit serotype 6E
pneumococci
Serotype 6E strain, vaccine,
and sample
Titer without
competitor
Titer with serotype 6A
PnPsa
%
Inhibition
Titer with serotype 6B
PnPsb
%
Inhibition
Titer with serotype 6C
PnPs
%
Inhibition
PMEN2
PCV7
209(6) 266 NAc NA 8 98.5 298 	12.0
214(6) 165 117 29.1 8 97.6 144 12.7
190(6) 3,462 3,738 	8.0 8 99.9 2,999 13.4
154(6) 2,005 1,361 32.1 8 99.8 1,397 30.3
042(7) 213 70 67.1 8 98.1 258 	21.1
PCV13
010A 766 708 7.6 8 99.5 684 10.7
208A 261 147 43.7 8 98.5 193 26.1
226A 1,995 1,684 15.6 8 99.8 1,337 33.0
240A 2,030 1,760 13.3 496 75.6 1,835 9.6
243A 3,069 433 85.9 NA NA 2,473 19.4
PMEN8
PCV7
209(6) 246 NA NA 8 98.4 237 3.7
214(6) 235 221 6.0 8 98.3 237 	0.9
190(6) 2,382 3,811 	60.0 8 99.8 2,692 	13.0
154(6) 2,151 1,755 18.4 8 99.8 1,894 11.9
042(7) 477 90 81.1 8 99.2 585 	22.6
PCV13
010A 484 536 	10.7 8 99.2 456 5.8
208A 111 72 35.1 8 96.4 75 32.4
226A 1,677 1,446 13.8 8 99.8 1,245 25.8
240A 1,979 1,803 8.9 533 73.1 2,153 	8.8
243A 2,769 328 88.2 8 99.9 2,117 23.5
VICEd 0629
PCV7
209(6) NA NA NA NA NA NA NA
214(6) 180 54 70.0 8 97.8 112 37.8
190(6) 2,024 1,877 7.3 8 99.8 1,858 8.2
154(6) 923 790 14.4 8 99.6 703 23.8
042(7) 8 8 0.0 8 0.0 8 0.0
PCV13
010A 420 199 52.6 8 99.0 193 54.0
208A NA NA NA NA NA NA NA
226A 681 509 25.3 8 99.4 566 16.9
240A 1,316 1,011 23.2 249 81.1 977 25.8
243A 1,419 117 91.8 8 99.7 1,109 21.8
VICE 1004
PCV7
209(6) 198 NA NA 8 98.0 194 2.0
214(6) 359 334 7.0 8 98.9 333 7.2
190(6) 2,514 2,424 3.6 8 99.8 2,238 11.0
154(6) 863 1,141 	32.2 8 99.5 762 11.7
042(7) 233 76 67.4 8 98.3 239 	2.6
PCV13
010A 421 488 	15.9 8 99.0 461 	9.5
208A 233 100 57.1 8 98.3 148 36.5
226A 2,626 241 90.8 NA NA 1,855 29.4
240A 1,791 1,394 22.2 8 99.8 1,257 29.8
243A 2,099 1,701 19.0 371 82.3 1,739 17.2
(Continued on following page)
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whether PCVs are protective against serotype 6E at the population
level.
Genomics has revolutionized microbiological research, and
our study reinforces just how influential the change has been and
will continue to be. It is now relatively simple and cost-effective to
use next-generation sequencing to obtain a (nearly) complete bac-
terial genome sequence, and the early challenges of contig assem-
bly, the availability of databases in which to store and query ge-
nome sequences, and the development of tools for the analysis of
large-scale databases are being overcome. There are currently
10,000 pneumococcal genome sequences available in public da-
tabases, and other genome sequencing projects are under way.
Challenges remain, including making published genome assem-
blies widely accessible to all users, but the genomics field ismoving
apace.
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